## (19) World Intellectual Property Organization

International Bureau



## . 1840 BANDAR H BIBNO 1811 BBN BBN BBN BIBL HA HA BBN BIBB I 1811 BBN BBN BBN BBN BLAND HA BBN BBN BBN BBN BBN

(43) International Publication Date 11 March 2004 (11.03.2004)

PCT

(10) International Publication Number WO 2004/021009 A2

(51) International Patent Classification7:

\_\_\_\_

G01N 33/574

(21) International Application Number:

PCT/CA2003/001311

(22) International Filing Date: 28 August 2003 (28.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/407,332


28 August 2002 (28.08.2002) U

(71) Applicant (for all designated States except US): MOUNT SINAI HOSPITAL [CA/CA]; 600 University Avenue, Toronto, Ontario M5G 1X5 (CA).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): YOUSEF, George [EG/CA]; 300 Prince Phillip Drive, St. John's. Newfoundland & Labrador A1B 3V6 (CA). DIAMANDIS, Eleftherios, P. [CA/CA]; 44 Gerrard Street West. Suite 1504. Toronto, Ontario M5G 2K2 (CA).
- (74) Agent: KURDYDYK, Linda: McCarthy Tetrault, Suite 4700, P.O. Box 48, 66 Wellington Street West, Toronto Dominion Bank Tower, Toronto. Ontario M5K 1E6 (CA).
- (81) Designated States (national): AE. AG, AL, AM, AT. AU. AZ, BA, BB, BG, BR, BY, BZ, CA. CH, CN. CO. CR, CU, CZ. DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR. KZ, LC. LK, LR. LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: METHODS FOR DETECTING ENDOCRINE CANCER



(57) Abstract: Kallikrein 13 constitutes a novel biomarker for diagnosis, treatment and monitoring of endocrine cancer. A method is provided for diagnosing and monitoring endocrine cancer or a predisposition to endocrine cancer, in a subject comprising detecting hK13 in a sample from the subject. Imaging methods, screening methods for test agents for inhibiting breast or ovarian cancer, and therapeutic applications based on kallikrein 13 are also described.